Ligand Pharmaceuticals, Inc. (LGND)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

3911 SORRENTO VALLEY BLVD SAN DIEGO, CA 92121

Ligand Pharmaceuticals is a biopharmaceutical company located in San Diego, California. Founded in 1987 as Progenx Inc., the company went public in 1992.

Data as of 2021-08-02 07:42:32 -0400
Market Cap1.89 Billion Shares Outstanding16.652 Million Avg 30-day Volume122.507 Thousand
P/E Ratio48.15494 Dividend Yield EPS2.4
Price/Sales9.07 Debt to Equity1.74 EBITDA79.869 Million
Price to Book Value2.53 Forward PE19.02 Enterprise Value1.909 Billion
Total Cash339.207 Million Current Debt95.805 Million Gross Profit174.519 Million
BETA0.74231 52-week High/Low219.75 / 78.26 Next Earnings Date Price to Cash FLow (P/CF) 72.8785
Data provided by IEX Cloud
View SEC Filings from LGND instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 5 2 150.0% 1 (0.06%) 1 (0.06%) 0.0%
Funds Holding: 222 236 -5.93% 53 (3.11%) 57 (3.31%) -7.02%
13F shares: 15.295 Million 22.825 Million -32.99% 3.701 Million 6.264 Million -40.92%
% Ownership 95.1123 23.0116 38.9519 -40.92%
New Positions: 35 30 16.67% 9 8 12.5%
Increased Positions 56 80 -30.0% 9 21 -57.14%
Closed Positions 47 41 14.63% 12 16 -25.0%
Reduced Positions 103 91 13.19% 29 24 20.83%
Total Calls 360.444 Thousand 322.998 Thousand 11.59% 64.9 Thousand 154 Thousand -57.86%
Total Puts 719.644 Thousand 1.751 Million -58.89% 65.2 Thousand 1.31 Million -95.02%
PUT/CALL Ratio 2.0 5.42 -63.1% 1.0 8.5 -88.24%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding LGND (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding LGND BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

COCHRAN JENNIFER R.

  • Director
0 2021-07-12 2

HIGGINS JOHN L CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
338,095 2021-06-30 8

KORENBERG MATTHEW E EVP,FINANCE & STRATEGY AND CFO

  • Officer
39,690 2021-06-30 4

ARYEH JASON

  • Director
128,552 2021-06-04 1

DAVIS TODD C

  • Director
54,051 2021-06-04 3

PATEL SUNIL

  • Director
32,089 2021-06-04 2

SABBA STEPHEN L

  • Director
30,798 2021-06-04 2

KOZARICH JOHN W

  • Director
38,051 2021-06-04 3

LAMATTINA JOHN L

  • Director
28,667 2021-06-04 1

GRAY NANCY RYAN

  • Director
6,971 2021-06-04 1

BOYCE SARAH

  • Director
6,161 2021-06-04 1

FOEHR MATTHEW W PRESIDENT AND COO

  • Officer
204,713 2021-05-28 5

BERKMAN CHARLES S SVP, GEN. COUNSEL & SECRETARY

  • Officer
27,891 2021-02-15 3

GOLDMAN SACHS GROUP INC

GOLDMAN SACHS & CO. LLC

686,330 2020-02-03 0

HERMAN MELANIE J DIRECTOR OF ACCOUNTING

  • Officer
3,454 2016-06-30 0

KNOTT DAVID M

  • Director
1,265,918 2015-08-17 0

DESILVA NISHAN M VP, FINANCE & STRATEGY AND CFO

  • Officer
22,282 2015-05-12 0

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BIOTECHNOLOGY VALUE FUND II LP

BVF INVESTMENTS LLC

BVF INC/IL

LAMPERT MARK N

  • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
No longer subject to file 2014-03-24 0

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BIOTECHNOLOGY VALUE FUND II LP

BVF INVESTMENTS LLC

INVESTMENT 10 LLC

BVF INC/IL

LAMPERT MARK N

  • 10% Owner
  • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
6,978,580 2014-02-18 0

SHARP JOHN P VP FINANCE AND CFO

  • Officer
17,667 2014-02-12 0

INVESTMENT 10 LLC

  • SEE EXPLANATION OF RESPONSES
3,582,065 2013-01-01 0

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BVF INC/IL

LAMPERT MARK N

  • 10% Owner
  • SEE EXPLANATION OF RESPONSES
741,627 2012-10-26 0

KAZMI SYED VP, BUS. DEV. & STRATEGIC PLAN

  • Officer
18,230 2012-02-09 0

MEGLASSON MARTIN V-P, DISCOVERY RESEARCH

  • Officer
102,250 2010-05-11 0

BURAKOFF STEVEN J

  • Director
15,000 2009-05-29 0

DZIEWANOWSKA ZOFIA E VP, CLINICAL RESEARCH

  • Officer
33,977 2009-02-25 0

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BIOTECHNOLOGY VALUE FUND II LP

BVF INVESTMENTS LLC

BVF INC/IL

  • 10% Owner
  • INDIRECT BENEFICIAL OWNERINDIRECT BENEFICIAL OWNERINDIRECT BENEFICIAL OWNERINDIRECT BENEFICIAL OWNERINDIRECT BENEFICIAL OWNER
16,006,215 2009-01-23 0

PEACOCK BRUCE

  • Director
10,000 2008-12-23 0

LIGAND PHARMACEUTICALS INC

  • Director
10,000 2008-08-04 0

GREETHAM ELIZABETH M

  • Director
10,000 2008-05-29 0

PERRY JEFFREY R

  • Director
33,953 2008-05-29 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

COCHRAN JENNIFER R. - Director

2021-07-14 20:19:46 -0400 2021-07-12 A 4,508 a 4,508 direct

COCHRAN JENNIFER R. - Director

2021-07-14 20:19:46 -0400 2021-07-12 A 1,161 a 1,161 direct -2.2794 5.569 7.1922 5 -2.2794 2

KORENBERG MATTHEW E - Officer EVP,FINANCE & STRATEGY AND CFO

2021-07-02 17:13:39 -0400 2021-06-30 J 247 $85.91 a 39,690 direct 0.0776 -5.3318 0.4269 4 -5.3318 6

HIGGINS JOHN L - Director - Officer CHIEF EXECUTIVE OFFICER

2021-07-02 17:14:09 -0400 2021-06-30 J 247 $85.91 a 338,095 direct 0.0776 -5.3318 0.4269 4 -5.3318 6

LAMATTINA JOHN L - Director

2021-06-07 21:24:03 -0400 2021-06-04 A 630 a 25,398 direct 0.7762 4.463 4.7414 17.582 14 -4.5136 28

SABBA STEPHEN L - Director

2021-06-08 14:26:24 -0400 2021-06-04 A 630 a 25,061 direct 0.7762 4.463 4.7414 17.582 14 -4.5136 28

BOYCE SARAH - Director

2021-06-07 21:25:43 -0400 2021-06-04 A 3,269 a 3,269 direct

PATEL SUNIL - Director

2021-06-07 21:23:28 -0400 2021-06-04 A 630 a 28,820 direct 0.7762 4.463 4.7414 17.582 14 -4.5136 28

ARYEH JASON - Director

2021-06-07 21:39:03 -0400 2021-06-04 A 3,269 a 3,269 direct

KOZARICH JOHN W - Director

2021-06-07 21:24:29 -0400 2021-06-04 A 630 a 34,782 direct 0.7762 4.463 4.7414 17.582 14 -4.5136 28

GRAY NANCY RYAN - Director

2021-06-07 21:24:58 -0400 2021-06-04 A 3,269 a 3,269 direct

BOYCE SARAH - Director

2021-06-07 21:25:43 -0400 2021-06-04 A 630 a 2,892 direct 0.7762 4.463 4.7414 17.582 14 -4.5136 28

DAVIS TODD C - Director

2021-06-07 21:25:22 -0400 2021-06-04 A 3,269 a 3,269 direct

ARYEH JASON - Director

2021-06-07 21:39:03 -0400 2021-06-04 A 630 a 68,664 direct 0.7762 4.463 4.7414 17.582 14 -4.5136 28

LAMATTINA JOHN L - Director

2021-06-07 21:24:03 -0400 2021-06-04 A 3,269 a 3,269 direct

SABBA STEPHEN L - Director

2021-06-08 14:26:24 -0400 2021-06-04 A 3,269 d 3,269 direct

GRAY NANCY RYAN - Director

2021-06-07 21:24:58 -0400 2021-06-04 A 630 a 3,702 direct 0.7762 4.463 4.7414 17.582 14 -4.5136 28

PATEL SUNIL - Director

2021-06-07 21:23:28 -0400 2021-06-04 A 3,269 a 3,269 direct

DAVIS TODD C - Director

2021-06-07 21:25:22 -0400 2021-06-04 A 630 a 50,782 direct 0.7762 4.463 4.7414 17.582 14 -4.5136 28

KOZARICH JOHN W - Director

2021-06-07 21:24:29 -0400 2021-06-04 A 3,269 a 3,269 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
LIGAND PHARMACEUTICALS LGND 2021-08-03 14:15:03 UTC -0.2011 0.2611 450000
LIGAND PHARMACEUTICALS LGND 2021-08-03 13:45:03 UTC -0.2011 0.2611 450000
LIGAND PHARMACEUTICALS LGND 2021-08-03 13:15:03 UTC -0.2011 0.2611 450000
LIGAND PHARMACEUTICALS LGND 2021-08-03 12:45:03 UTC -0.2011 0.2611 450000
LIGAND PHARMACEUTICALS LGND 2021-08-02 22:15:03 UTC -0.2011 0.2611 400000
LIGAND PHARMACEUTICALS LGND 2021-08-02 21:45:03 UTC -0.2011 0.2611 400000
LIGAND PHARMACEUTICALS LGND 2021-08-02 21:15:03 UTC -0.2011 0.2611 400000
LIGAND PHARMACEUTICALS LGND 2021-08-02 20:45:03 UTC -0.2058 0.2658 400000
LIGAND PHARMACEUTICALS LGND 2021-08-02 20:15:03 UTC -0.2058 0.2658 400000
LIGAND PHARMACEUTICALS LGND 2021-08-02 19:45:03 UTC -0.2058 0.2658 400000
LIGAND PHARMACEUTICALS LGND 2021-08-02 19:15:03 UTC -0.2058 0.2658 400000
LIGAND PHARMACEUTICALS LGND 2021-08-02 18:45:03 UTC -0.2053 0.2653 400000
LIGAND PHARMACEUTICALS LGND 2021-08-02 18:15:03 UTC -0.2053 0.2653 400000
LIGAND PHARMACEUTICALS LGND 2021-08-02 17:45:03 UTC -0.2053 0.2653 400000
LIGAND PHARMACEUTICALS LGND 2021-08-02 17:15:03 UTC -0.2053 0.2653 400000
LIGAND PHARMACEUTICALS LGND 2021-08-02 16:45:03 UTC -0.1874 0.2674 400000
LIGAND PHARMACEUTICALS LGND 2021-08-02 16:15:03 UTC -0.1874 0.2674 400000
LIGAND PHARMACEUTICALS LGND 2021-08-02 15:45:03 UTC -0.1874 0.2674 400000
LIGAND PHARMACEUTICALS LGND 2021-08-02 15:15:03 UTC -0.1874 0.2674 400000
LIGAND PHARMACEUTICALS LGND 2021-08-02 14:45:03 UTC -0.17 0.25 400000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
FundVantage Trust- Gotham Enhanced Index Plus Fund LGND -6.0 shares, $-436.32 2020-03-31 N-PORT
FundVantage Trust- Gotham Defensive Long Fund LGND -62.0 shares, $-4508.64 2020-03-31 N-PORT
AQR Funds- AQR Large Cap Relaxed Constraint Equity Fund LGND -465.0 shares, $-46286.1 2019-09-30 N-PORT
FundVantage Trust- Gotham Index Plus All-Cap Fund LGND -43.0 shares, $-3126.96 2020-03-31 N-PORT
UBS RELATIONSHIP FUNDS- UBS U.S. EQUITY ALPHA RELATIONSHIP FUND LGND -18048.0 shares, $-2018668.8 2020-06-30 N-PORT
THE LAZARD FUNDS, INC.- Lazard Enhanced Opportunities Portfolio LGND -551.0 shares, $-83999.95 2021-03-31 N-PORT
TIFF INVESTMENT PROGRAM- TIFF Multi-Asset Fund LGND -636.0 shares, $-96958.2 2021-03-31 N-PORT
AMERICAN BEACON FUNDS- American Beacon SSI Alternative Income Fund LGND -3394.0 shares, $-517415.3 2021-03-31 N-PORT
AQR Funds- AQR Alternative Risk Premia Fund LGND -80.0 shares, $-12196.0 2021-03-31 N-PORT
AQR Funds- AQR Multi-Asset Fund LGND -79.0 shares, $-12043.55 2021-03-31 N-PORT
JNL Series Trust- JNL/AQR Large Cap Relaxed Constraint Equity Fund LGND -956.0 shares, $-145742.2 2021-03-31 N-PORT
JNL Series Trust- JNL Multi-Manager Alternative Fund LGND -3868.0 shares, $-589676.6 2021-03-31 N-PORT
Morningstar Funds Trust- Morningstar Alternatives Fund LGND -1061.0 shares, $-154789.29 2021-04-30 N-PORT
Franklin Alternative Strategies Funds- Franklin K2 Alternative Strategies Fund LGND -1648.0 shares, $-193969.6 2021-05-28 N-PORT

Elevate your investments